These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 27097113

  • 1. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.
    Oncotarget; 2016 May 31; 7(22):32046-53. PubMed ID: 27097113
    [Abstract] [Full Text] [Related]

  • 2. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H.
    Leuk Lymphoma; 2009 Aug 31; 50(8):1361-8. PubMed ID: 19562616
    [Abstract] [Full Text] [Related]

  • 3. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.
    Clin Cancer Res; 2008 Jul 15; 14(14):4650-7. PubMed ID: 18628480
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
    Hassenrück F, Knödgen E, Göckeritz E, Midda SH, Vondey V, Neumann L, Herter S, Klein C, Hallek M, Krause G.
    Biomed Res Int; 2018 Jul 15; 2018():1023490. PubMed ID: 29750146
    [Abstract] [Full Text] [Related]

  • 8. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanović S, Dörfel D, Schneider P, Salih HR.
    Leukemia; 2015 Aug 15; 29(8):1676-83. PubMed ID: 25710310
    [Abstract] [Full Text] [Related]

  • 9. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
    Akhiani AA, Hallner A, Kiffin R, Aydin E, Werlenius O, Aurelius J, Martner A, Thorén FB, Hellstrand K.
    Cancer Immunol Res; 2020 Dec 15; 8(12):1532-1541. PubMed ID: 32967913
    [Abstract] [Full Text] [Related]

  • 10. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 15; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 11. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL, Merle-Beral H, Vieillard V.
    Leukemia; 2011 Jan 15; 25(1):101-9. PubMed ID: 20975664
    [Abstract] [Full Text] [Related]

  • 12. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
    VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS.
    Cancer Immunol Res; 2018 Oct 15; 6(10):1150-1160. PubMed ID: 30089638
    [Abstract] [Full Text] [Related]

  • 13. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
    Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Seda V, Fojtova M, Fajkus J, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M.
    Leukemia; 2018 Sep 15; 32(9):2028-2031. PubMed ID: 30030508
    [No Abstract] [Full Text] [Related]

  • 14. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
    Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, Paolini R, Santoni A, Galandrini R.
    Cancer Res; 2015 Oct 01; 75(19):4097-108. PubMed ID: 26229120
    [Abstract] [Full Text] [Related]

  • 15. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW.
    Br J Haematol; 2013 Oct 01; 163(2):182-93. PubMed ID: 23927424
    [Abstract] [Full Text] [Related]

  • 16. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J.
    Blood; 2002 Feb 15; 99(4):1314-9. PubMed ID: 11830481
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
    Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A.
    J Immunol; 2013 Oct 01; 191(7):3634-40. PubMed ID: 23997218
    [Abstract] [Full Text] [Related]

  • 18. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C.
    Front Immunol; 2019 Oct 01; 10():1943. PubMed ID: 31475004
    [Abstract] [Full Text] [Related]

  • 19. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC.
    Blood; 2008 Dec 15; 112(13):5180-9. PubMed ID: 18772452
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression.
    Moga E, Cantó E, Vidal S, Juarez C, Sierra J, Briones J.
    Exp Hematol; 2011 Nov 15; 39(11):1064-71. PubMed ID: 21864486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.